K. Gergich

发表

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Lon Smith, Omar Laterza, Robert H Pierce, 2015, Clinical Cancer Research.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression

J. Lunceford, M. Dolled-Filhart, K. Emancipator, 2014 .

Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.

A. Tolcher, K. Papadopoulos, M. Beeram, 2012 .

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

D. D. de Alwis, E. Rubin, G. Lubiniecki, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study.

P. Ponikowski, C. O'connor, M. Metra, 2010, Journal of cardiac failure.

Effects of ethanol on protein kinase C activity induced by filamentous actin.

S. Milano, S. Slater, C. Stubbs, 2001, Biochimica et biophysica acta.

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

J. Wolchok, H. Zarour, A. Ribas, 2015 .

Synergistic activation of protein kinase Calpha, -betaI, and -gamma isoforms induced by diacylglycerol and phorbol ester: roles of membrane association and activating conformational changes.

M. B. Kelly, C. Ho, S. Milano, 1999, Biochemistry.

Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).

J. Wolchok, A. Ribas, F. Hodi, 2014 .

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Interaction of protein kinase C with filamentous actin: isozyme specificity resulting from divergent phorbol ester and calcium dependencies.

S. Milano, S. Slater, C. Stubbs, 2000, Biochemistry.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2016, JAMA.

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

J. Lunceford, M. Dolled-Filhart, K. Emancipator, 2014 .

Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2013 .